Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › DREAMS-3

DREAMS-3

Mazdutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Mazdutide
Population
t2d
Official title
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
3
Registry status
completed · 2024-02 → 2025-09
Participants
349
Duration
32 weeks
Registry
NCT06184568

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
6 mg vs semaglutide 1 mg: weight -6.0 %, HbA1c -1.84t2d china32349——−10.3 %
estimand not specified
−2.0——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • 6 mg · hba1c · press release
    the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group
  • 6 mg · weight_unsp · press release
    the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6.00% in the semaglutide group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: DREAMS-3. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.